Clinical data | |
---|---|
Other names | PF-04171327; PF-4171327; Dagrocorat 2-(dihydrogen phosphate); Dagrocorat dihydrogen phosphate |
Drug class | Selective glucocorticoid receptor modulator |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C29H30F3N2O5P |
Molar mass | 574.537 g·mol−1 |
3D model ( JSmol) | |
| |
|
Fosdagrocorat (developmental code names PF-04171327 and PF-4171327; also known as dagrocorat 2-(dihydrogen phosphate)) is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed. [1] [2] [3] [4] It is the C2 dihydrogen phosphate ester of dagrocorat, and acts as a prodrug of dagrocorat with improved pharmacokinetics. [5] [6] The drug reached phase II clinical trials prior to the discontinuation of its development. [1] [3] [4]